AI is in Every Pharma Strategy Deck
Beyond Reporting - Safety surveillance analytics for medical devices...
Electronic Logs - The next phase of execution maturity in pharma
Maximising Patient Engagement in Clinical Trials
From Snapshots to Movies
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Digital Transformation in Pharma Manufacturing | David Holt, FactoryTalk | ISPE 2026 | Pharma Focus Asia
Group Executive Director, FactoryTalk
David Holt is the Group Managing Director at Factory Talk with extensive leadership experience across multiple industries He focuses on innovative software solutions that enable the digital transformation of operations within GxP pharmaceutical and medical deviceregulated industries
Articles
Untapped Opportunities in Southeast Asia
Southeast Asia is a growing pharmaceutical market with an increase in clinical trials in recent years With a population of about million and a total area of million kilometres it contains the regions wellrecognised study destinations of Malaysia Singapore and Thailand who are also members of PICS the Pharmaceutical Inspection Cooperation Scheme B
Research Insights
An mRNA Vaccine for Pancreatic Cancer Designed by Applying in Silico Immunoinformatics and Reverse Vaccinology Approaches
Pancreatic ductal adenocarcinoma PDAC which constitutes of pancreatic cancer PC is the fourth most prevalent cause of cancerrelated mortality globally A study suggests that by the number of deaths in the US from PC will surpass that from breast
Case Studies
High Concentration Antibody - Rituximab
Challenge Antibodies tend to aggregate at the high concentrations typically required for their therapeutic application The key challenge of this study was to reduce the rate of aggregation in isotonic aqueous formulation of rituximab at mgml whilst maintai
Techno Trends
Encoded Therapeutics has Introduced ETX101 for the Treatment of Patients with Dravet Syndrome
Encoded Therapeutics has introduced ETX for the treatment of SCNA Dravet syndrome a rare and severe genetic neurological disorder that begins in early childhood
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
The Growing Role of Biocatalysis in Industrial Synthesis
Dr Reuben Carr has over 25 years of experience in developing proprietary biocatalytic processes for fine chemical and pharmaceutical manufacturing. He specialises in using directed evolution to engineer natural enzymes to carry out novel chemical reactions, enabling the synthesis of challenging molecular targets for clients and customers.
Transforming Customer Engagement in Life Sciences Adopting Hybrid Commercial Models (HCMs)
is a Practice Director at the Life Sciences IT Services team, leading commercial technology research and client engagements. He has worked with business and IT leaders on strategy, M&A, and market intelligence. Previously a Consultant at EY, Rohit holds an MBA from FMS, Delhi University, and an engineering degree from NIT Jalandhar.
Marine Biomaterials for Drug Delivery Applications
Macha has six years of experience in research and teaching in the area of biomaterials synthesis and characterisations, drug delivery devices, cell culture and bacterial biofilm. He is also Associate Editor of the Journal of The Australian Ceramic Society and has published more than 14 articles and 6 book chapters.
Precision medicine for Alzheimer’s Disease
Dr Parmi is a scientific researcher and an expert medical writer with Ph.D specialising in neurosciences. With an extensive pharmaceutical and healthcare industry experience, she excels at driving innovation. Focused at patient’s centricity, she has played key role in developing innovative medicines that makes meaningful impact on patient’s lives. Dr Parmi has made significant contribution at establishing a patented mouth-dissolving strip (MDS) manufacturing facility. With proven expertise in novel product development, her strong emphasis on quality manufacturing has led to structuring of quality documentation practices for this novel & patented MDS technology aligned with regulatory standards.
Dr Parmi has made significant contributions in field of neuroscience research with multiple acclaimed publications. A distinguished medical writer, she serves as editorial board member and peer reviewer in prestigious journals and continuous to make an impact in her field. Author at reputed public health platform, she writes to promote health awareness. Recognised for her exceptional contributions, she is a multiple-time government R&D grant recipient, particularly in neurodegenerative disorder studies.
Why Pharma's Safety Net Must Follow the Medicine Home
Barbara works closely with leaders across pharmaceutical, medical devices and solution providers serving healthcare organisations - all of whom are using digital product identities.
Much of her time is spent with product owners and senior leaders in packaging, operations, anti-counterfeit, manufacturing, and with system integrators. She is focused on protecting patient safety at scale, serving leadership with trusted data and improving efficiency through innovative solutions.
Barbara's background spans innovation strategy, partnership development, marketing and commercial roles and cross-functional leadership in highly regulated settings. She is known for her collaborative and pragmatic approach, working alongside teams to explore long-term roadmaps that balance progress with responsibility.
Barbara cares deeply about how healthcare systems evolve without compromising what matters most. She is always open to conversations with leaders who are navigating similar challenges and looking to move forward responsibly.
press releasesRead more...
Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
Pfizer Inc NYSE PFE and Blackstone Life Sciences Blackstone today announced a strategic cofunding agreement under which funds managed by Blackstone will pay up to a total of billion of development
Circio and Solid Biosciences enter collaboration to evaluate circVec and POLARIS-101 technology for Genetic Heart Disease
Circio Holding ASA OSE CRNA a biotechnology company developing novel circular RNA expression technology for gene and cell therapy today announces a research collaboration with Solid Biosciences Inc
EirGenix and Merck enter Partnership to Strengthen Global Biologics Development Through Integrated BioReliance® Testing and Regulatory Support
EirGenix Inc and Merck have signed a nonlegally binding memorandum of understanding MOU to support EirGenixs IND and BLA enabling biologics pipeline development The MOU outlines Merck as one of EirGenixs preferred contract testing services vendors providing comprehensive BioReliance services
ProBio Enters Exclusive Global Licensing Agreement with AbTis to Develop Next-Generation ADC Asset
ProBio a global contract research development and manufacturing organization CRDMO today announced that it has entered into an exclusive global licensing agreement with AbTis Co Ltd
AGC Biologics partners with Child’s Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder
In a world where patients with CDKL deficiencies can suffer to epileptic seizures a day a contract biopharmaceutical manufacturer and a parentfounded foundation will partner on earlystage
Rakovina Therapeutics Secures Exclusive Worldwide Licence to Artemis.AI™ Platform for DNA-Damage Response Oncology Drug Discovery
Rakovina Therapeutics Inc TSXV RKV FSE JO OTCMKTS RKVTF a biopharmaceutical company advancing innovative cancer therapies through AIpowered drug discovery today announced
EventsRead more...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
LATEST NEWSRead more...
Natera Enters into Collaboration with Incyte for Phase II Trial in Colorectal Cancer
Natera a precision medicine company has entered into a clinical collaboration with Incyte to support a new Phase II study evaluating an investigational treatment for colorectal cancer CRC
Shionogi Enters into Licence Agreement with Link for Antibiotic Cefiderocol
Shionogi has entered into a licence agreement with Link Healthcare Singapore to develop and commercialise cefiderocol in Singapore and Malaysia
IDEL Therapeutics Partners with Daiichi Sankyo to Develop Multi-Drug Conjugates for Solid Tumours
IDEL Therapeutics has entered into a global research collaboration with Daiichi Sankyo to evaluate a multidrug conjugate MDC using iDELs synthetic shuttle platform for the treatment of selected solid tumours The multiyear collaboration will focus on the preclinical evaluation of a new class of MDCs...
Bayer’s Asundexian Receives Approval for Secondary Stroke Prevention
Bayer has received approval from the US Food and Drug Administration FDA for asundexian mg tablets marketed under the brand name Sunharbo to reduce the risk of recurrent stroke in adults following a recent noncardioembolic ischaemic stroke or highrisk transient ischaemic attack TIA
Johnson & Johnson Receives Approval for RYBREVANT FASPRO to Treat Advanced Head and Neck Cancer
Johnson Johnson has received accelerated approval from the US Food and Drug Administration FDA for RYBREVANT FASPRO amivantamab and hyaluronidaselpuj to treat adults with recurrent or metastatic head and neck squamous cell carcinoma HNSCC
Boehringer Ingelheim Enters into Partnership with SBP Group to Advance Next-Generation Cancer Therapies
Boehringer Ingelheim and Sino Biopharmaceutical SBP Group have entered into a multiprogram partnership to develop potential nextgeneration cancer treatments using antibodydrug conjugate ADC and Tcell engager TcE technologies
